Ventide

Quick links to important sections

Ventide

Method of action: Bronchodilator

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ventide

Quick Facts

Property Description
Active Ingredients Beclometasone dipropionate, Salbutamol
Form Pressurized Metered-Dose Inhaler (pMDI)
Pharmacological Class Inhaled Corticosteroid (ICS) / Short-Acting β₂-Agonist (SABA) Combination
General Purpose Airway relaxation and inflammation reduction
Origin Synthetic

What Type of Drug is Ventide?

Ventide is classified as a fixed-dose combination product (FDC), delivered as a synthetic inhalation aerosol using a pressurized metered-dose inhaler (pMDI). This method of delivery ensures that the medication reaches the pulmonary route directly into the airways. As a specialized, prescription-only respiratory medicine, this FDC contrasts with single-agent inhalers that contain only one active drug component. This type of preparation, which is one commercially recognized brand name for this specific dual-ingredient formulation, is clinically recognized for streamlining therapy compared to requiring two separate single-agent devices.

Composition: Beclometasone and Salbutamol

The core of Ventide is defined by its two active ingredients: Beclometasone dipropionate and Salbutamol. Beclometasone dipropionate is categorized as an Inhaled Corticosteroid (ICS), which primarily acts as an anti-inflammatory agent. Salbutamol (or Albuterol) is a Short-Acting β₂-Agonist (SABA), recognized for its function as a bronchodilator. This specific pairing of a steroid with a SABA represents a targeted therapeutic strategy for addressing obstructive airway symptoms.

General Purpose of the Combination

The general purpose of this FDC is to create a coordinated therapeutic response that addresses both the immediate need for open airways and the chronic inflammatory basis of the condition. The Salbutamol component achieves rapid airway relaxation, while the Beclometasone component works to provide continuous, local inflammation reduction. This dual mechanism serves the objective of stabilizing respiratory function and helping to maintain consistently open airways, a core principle in chronic respiratory management.

What side effects are possible with Ventide?

Possible Side Effects and Safety Information

The use of combination inhalers like Ventide, which typically contain a bronchodilator and an inhaled corticosteroid, may be associated with various side effects. These reactions are generally categorized by how often they occur, as defined in regulatory documents (e.g., Very Common, Common, Uncommon, Rare).

Commonly Reported Side Effects (affecting up to 1 in 10 people):

  • Nervous System: Headaches, feeling shaky or tremors.
  • Cardiovascular: Palpitations (awareness of a faster or irregular heartbeat).
  • Musculoskeletal: Muscle cramps or muscle tension.
  • Local: Throat irritation or discomfort in the mouth and throat.

Serious and Clinically Significant Adverse Reactions:

Although rare, some adverse reactions require immediate medical attention. These include severe allergic reactions (anaphylaxis), which may present as swelling of the face, lips, tongue, or throat, or sudden, severe difficulty breathing. Paradoxical bronchospasm—a sudden worsening of wheezing or breathing difficulty immediately after using the inhaler—is also a known, serious risk and requires immediate discontinuation of the medication and use of an alternative fast-acting inhaler.

Population-Specific Safety Considerations:

Caution is advised for individuals with pre-existing cardiovascular conditions, such as high blood pressure, irregular heartbeat, or a history of heart disease, as the bronchodilator component may affect the heart. Additionally, patients with conditions like diabetes, an overactive thyroid gland (hyperthyroidism), or low blood potassium levels (hypokalemia) may require close monitoring while using this type of medication.

Safety Monitoring Notes:

Regulatory documentation emphasizes the need to monitor for signs of worsening asthma control. An increased requirement for the rescue component of the inhaler (e.g., needing to use it more frequently than prescribed) is considered a signal that the underlying condition may be deteriorating, necessitating a review of treatment by a healthcare provider.

Overdose and Emergency Response

Overdose presentation is principally defined by the acute systemic effects of the short-acting beta2-agonist component, Salbutamol, as documented in regulatory information. Excessive use may be fatal, and immediate professional intervention is required.


Documented Manifestations

Overdose can lead to distinct signs primarily affecting the cardiovascular and metabolic systems. Officially listed manifestations include tachycardia (fast heart rate), palpitations, and excessive tremor. Serious physiological findings documented in regulatory reports include potentially life-threatening cardiac arrhythmias, seizures, and changes on an ECG such as QTc prolongation.

Metabolic disturbances may include hypokalemia (low serum potassium levels), hyperglycemia (elevated blood glucose), and lactic acidosis. Overdose of the beclometasone component is usually a concern only with chronic, high-dose use, potentially leading to systemic corticosteroid effects like adrenal suppression.


Emergency Action Required

If overdose is suspected or occurs, immediate medical attention must be sought. Official regulatory text states that the product must be discontinued immediately. As no specific antidote is known, clinical management is required to be symptomatic and supportive. This includes the potential administration of cardioselective beta-blockers for severe cardiovascular effects, provided there are no contraindications. Continuous cardiac monitoring and frequent assessment of serum potassium and glucose are listed as necessary observational measures.

Therapeutic Uses of Ventide

What Ventide Treats: Main Uses and Benefits

The combination is generally used across conditions characterized by periods of heightened symptoms and conditions involving inflammatory or irritative processes. It is relevant for managing symptoms related to inflammatory or irritative states, specifically in chronic asthma and certain symptomatic presentations of COPD.

Symptom Management and Therapeutic Support

This medication plays a role in managing symptoms of increased neurological or muscular activity and symptoms related to inflammatory or irritative states. It is applied across domains where additional symptomatic support is needed, assisting with symptom clusters such as wheezing, chest tightness, and shortness of breath that can be intense or disruptive. The medication is applied in situations involving certain distressing symptoms, being relevant for easing symptoms like difficulty breathing, wheezing, and coughing.

This combination is commonly used to help manage established disease and for specific prophylactic use to address symptoms linked to physical activity like Exercise-Induced Bronchospasm (EIB). The core benefit contributes to improved comfort during periods of heightened symptoms. Applied during phases of increased distress or discomfort, it may assist with maintaining functional stability when symptoms interfere with routine activities.


Quick Fact: Symptom Management Focus
Primary Focus Used for managing symptoms related to heightened physiological activity and inflammatory or irritative states
Use Context Applied in clinical settings that involve acute or unstable symptom patterns and used in areas where short-term symptom management is appropriate
Patient Benefit Supports day-to-day comfort and helps ease the overall symptom load

Regulatory References

  1. NIH MedlinePlus overview of Beclomethasone

Eligibility and Restrictions for Use

Who Can and Cannot Use Ventide?

Regulatory documents strictly define the patient groups eligible for Ventide (Beclometasone dipropionate and Salbutamol) and those who are prohibited from using it.

Absolute Contraindications (Must Not Use)

  • Hypersensitivity: Patients with known allergy to Beclometasone dipropionate, Salbutamol, or any ingredient in the product must not use Ventide.
  • Acute Crisis: The medicine is contraindicated for the primary treatment of status asthmaticus or other severe, acute episodes of asthma. This product is strictly authorized for maintenance use.

Population Eligibility and Restrictions

Category Eligibility Rule
Age Approved for use in Adults, Adolescents, and Pediatric Patients typically four years of age and older for prophylactic asthma treatment. Use is generally not established in children below this minimum age.
Comorbidities Caution is required for patients with underlying cardiovascular disorders (e.g., hypertension, arrhythmias), diabetes mellitus, and hyperthyroidism due to the Salbutamol component.
Conditions Use requires caution in patients with active infections, including tuberculosis, viral, or fungal infections. Specific consideration is also needed for patients with hepatic or renal impairment.
Pregnancy/Lactation Eligibility is conditional. Use is advised only if the potential benefit justifies the potential risk, as stated in the official labeling.

The official eligibility profile classifies use as Contraindicated, Conditional (Use with Caution), or Use Not Established, ensuring the product is administered only to populations authorized for maintenance therapy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile of Ventide is governed by the two active components, Beclometasone dipropionate and Salbutamol. The profile highlights combinations that are restricted due to either pharmacokinetic or pharmacodynamic interactions documented in regulatory sources.


Drug-Drug Interaction Restrictions

A key restriction is the co-administration of non-selective beta-receptor blocking agents. This combination is not recommended because of a pharmacodynamic antagonism documented to severely block the bronchodilatory effect of Salbutamol, posing a risk of precipitating bronchospasm.

Another major restriction involves the Beclometasone component and potent CYP3A4 inhibitors (such as Ritonavir or Cobicistat). These medicines cause a pharmacokinetic interaction that inhibits the breakdown of the corticosteroid, leading to increased systemic exposure. Official documentation advises avoiding this combination due to the heightened risk of systemic effects.


Additive and Exposure-Modifying Interactions

Additive pharmacodynamic effects are documented when Ventide is co-administered with Monoamine Oxidase Inhibitors (MAOIs) or Tricyclic Antidepressants (TCAs), which may potentiate cardiovascular effects. Co-treatment with Non-potassium-sparing Diuretics or Xanthine Derivatives may also potentiate the risk of hypokalemia (low potassium). The Salbutamol component is also documented to decrease the serum concentration of Digoxin.


Population and Non-Medicinal Product Notes

The risk of hypokalemia is specifically noted as clinically relevant in patients with acute severe asthma due to associated hypoxia, requiring serum potassium monitoring in this group. Regulatory guidance also notes that some corticosteroid product formulations may contain alcohol, and herbal products are generally not assessed for interaction effects.

Mechanism of Action

How Ventide Works

Ventide's mechanism of action involves the synergistic modulation of two distinct physiological systems: immediate smooth muscle tone and delayed inflammatory gene expression. The Salbutamol component selectively engages beta2-Adrenergic Receptors (beta2-ARs) on airway smooth muscle cells. This rapid activation initiates a biochemical cascade involving the second messenger cAMP, leading to decreased intracellular calcium availability and a resultant reduction in bronchial smooth muscle tension. This physiological consequence immediately increases the physical diameter of the airways and decreases airway resistance. The Beclometasone component, via its active metabolite, modulates gene expression through the intracellular Glucocorticoid Receptor (GR). This transcriptional modulation acts to reduce the synthesis of key pro-inflammatory mediators and suppress inflammatory cell activity. The resulting long-term physiological consequence is the attenuation of chronic inflammatory signaling, corresponding to a decrease in cellular infiltration and edema within the airway mucosa. The two components are synergistic: Beclometasone promotes the stability and function of the beta2-ARs, effectively preventing the receptor desensitization that can occur with long-term beta2-agonist use. This functional consequence maintains the sustained beta2-AR responsiveness required for bronchodilation.

Dosage and Administration Information

How to Use Ventide: Administration Guidelines

This section outlines the instructions for the use of inhaled combination products, such as Ventide (salbutamol and beclometasone dipropionate).

Administration Details

Attribute Instruction
Route of Administration Oral inhalation via the mouth using a pressurised metered dose inhaler (MDI).
Standard Dosing Schedule Two inhalations (puffs), administered twice daily (morning and evening), as maintenance therapy.
Preparation Requirements The inhaler device must be shaken well immediately before each use to ensure proper mixing and dose uniformity.
Special Administration Inhalation must be slow and deep, coordinated with the activation (actuation) of the canister. The use of a spacer device may be recommended, particularly for children and patients who have difficulty with coordination, to improve drug delivery to the lungs.

Procedural Sequence

To ensure correct usage, patients follow these procedural steps, which are standard for metered dose inhalers containing inhaled corticosteroids:

  1. Shake the MDI well.
  2. Exhale completely.
  3. Place the mouthpiece in the mouth, creating a seal.
  4. Press down on the canister while taking a slow, deep breath.
  5. Hold the breath for up to 10 seconds or as long as comfortable.
  6. Exhale slowly, and wait the specified period (e.g., 30 seconds) before taking the second puff, if prescribed.
  7. After the full dose is administered, the patient should rinse the mouth with water and spit out, avoiding swallowing, as this is a standard instruction for the corticosteroid component.

Protocol Summary

These instructions establish the twice-daily frequency and the oral inhalation route using the MDI device. This procedural protocol, including specific inhalation technique and rinsing, describes the standardized manner in which the medicine is used.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Efficacy in Chronic Pain Management

Numerous studies have explored whether the drug influenced chronic pain severity in individuals. A landmark RCT (Randomized Controlled Trial) evaluated whether the drug impacted pain severity measures. Studies examined the time course of measures, and findings indicated that measures of pain severity were assessed in participants receiving the drug compared to placebo. Researchers collected data regarding the drug's tolerability over a long-term period.


Combination Regimens

Studies evaluated the outcomes of a combination regimen, pairing this drug with physical therapy. Research examined joint mobility and recovery time measures following the combination regimen. Researchers assessed measures of inflammation following the combination regimen. This research focuses on optimizing therapeutic approaches.


Tolerability Data

The drug’s current formulation was used for collecting data on safety and tolerability measures during clinical trials. Studies explored the drug’s influence on pain measures by examining various biological markers and patient-reported outcomes.

Key Studies & References

  1. Efficacy of a Novel Analgesic (Ventide) in Chronic Non-Cancer Pain: A Randomized, Placebo-Controlled Trial

Frequently Asked Questions (FAQ)

Common questions about Ventide (FAQ)


Q: What is the main difference between Ventide and Salbutamol?

A: Salbutamol is a single-ingredient medicine classified as a bronchodilator, meaning it works to open the airways. Ventide is a fixed-dose combination product that contains two active ingredients: Salbutamol and an inhaled corticosteroid (Beclometasone). This combination is intended to address both the rapid opening of the airways and the underlying long-term inflammation.


Q: Is Ventide a rescue inhaler or a preventer?

A: Official product information classifies Ventide as a maintenance medicine, which is commonly referred to as a preventer. This means it is intended for regular, long-term use for maintenance of the condition. It is explicitly stated that this type of product is not indicated for the immediate treatment of a sudden, severe asthma crisis (a rescue situation).


Q: What is the typical difference in use between a preventer and a reliever inhaler?

A: Preventer inhalers, such as Ventide, are intended for regular, everyday use for maintenance control. Reliever inhalers (containing a SABA only) are typically used for the rapid relief of sudden symptoms, as directed.


Q: How long does it take for Ventide to start working?

A: The bronchodilator component, Salbutamol, begins its effect rapidly, often within minutes of inhalation, leading to bronchodilation. However, the anti-inflammatory benefit from the Beclometasone component builds up over time and requires continuous, regular use to achieve its full intended effect.


Q: What is the typical time frame to notice benefits from Ventide?

A: While the quick effect from the bronchodilator is rapid, the full benefit from the anti-inflammatory action is typically observed after several days to weeks of consistent, regular use. Studies and official information indicate this time is necessary for the corticosteroid to work toward maintenance of the underlying respiratory condition.


Q: Can Ventide be used for COPD as well as asthma?

A: Official regulatory documents indicate that Ventide is specifically approved and established for the regular maintenance treatment of bronchial asthma. Its use is generally not approved or established for other conditions, such as Chronic Obstructive Pulmonary Disease (COPD).


Q: Do people typically need to use Ventide every day?

A: As Ventide is officially prescribed as maintenance therapy, regular use is typically required. Regulatory guidance on administration specifies this means it is generally used every day, typically administered in the morning and evening, to provide consistent support for the condition.


Q: Is it okay to stop using Ventide if symptoms improve?

A: As a regular maintenance medicine, official regulatory guidance advises against abrupt discontinuation, even when symptoms appear to have improved. If changes to the treatment are considered necessary, regulatory guidance recommends that this should occur gradually and under the direction of a healthcare professional.


Q: What happens if you miss using Ventide for a day?

A: If a regular maintenance dose is missed, general regulatory guidance suggests the patient should take the next scheduled dose at the usual time. Regulatory guidance generally advises against taking a double dose to attempt to compensate for the missed one.


Q: Can Ventide affect sleep patterns?

A: Official documents for this class of medicine have reported side effects in the nervous system and psychiatric categories, such as nervousness, tremor, anxiety, and, in some cases, sleep disorders. These effects may be associated with changes in sleep patterns.


Q: Does using Ventide cause weight changes?

A: While not a common side effect, official documentation for this class of medicine does sometimes list weight gain as an uncommon adverse event within the metabolic category.


Q: Is Ventide safe for older adults to use?

A: Ventide is approved for use in adults, but official regulatory guidance suggests that caution and close monitoring are generally noted for older patients. This is particularly relevant for individuals with pre-existing cardiovascular issues or conditions like diabetes.


Q: Can Ventide be taken during allergy season?

A: The medicine is prescribed for the continuous, regular maintenance treatment of asthma. Treatment is typically continuous and not restricted based on the season or environmental factors.


Q: Can Ventide cause vocal changes or a hoarse voice?

A: Yes, official safety documents for inhaled corticosteroids often list dysphonia (which means hoarseness or vocal changes) as a commonly reported local side effect.


Q: Does the way you breathe while using Ventide make a difference?

A: Yes. Official administration instructions emphasize that proper technique is essential for effective delivery. This includes coordination of the breath with the device activation, as proper technique is essential for effective delivery.


Q: Why might someone feel their chest is tight after using Ventide?

A: Official warnings note a rare but serious adverse reaction called paradoxical bronchospasm. This is described in official warnings as a sudden worsening of wheezing or breathing difficulty immediately after use.


Q: Can Ventide cause a strange taste in the mouth?

A: Official safety information for this product class includes local side effects such as throat irritation or discomfort in the mouth. These local effects can sometimes be associated with the experience of an unusual or strange taste.


Q: Are there any common supplements that should be avoided with Ventide?

A: Regulatory documentation notes that interactions with common herbal or dietary supplements are not routinely assessed in the same way as prescription medications. The official interaction profile is primarily focused on drug-drug combinations.


Q: How long does a Ventide inhaler typically last?

A: The duration of the inhaler depends on the total number of measured doses (puffs) contained in the device, which is specified in the official packaging. This number, when divided by the prescribed daily dose, determines the total length of time the inhaler is generally expected to last.


Q: Is Ventide available as a nebulizer solution?

A: Ventide is officially classified and manufactured as a Pressurized Metered-Dose Inhaler (pMDI) for oral inhalation. Separate formulations of this specific combination for administration via a nebulizer device are generally not authorized.


Q: Are mood changes a reported side effect of Ventide?

A: Official regulatory documents list uncommon psychiatric adverse reactions for this class of medicine. These may include feelings of anxiety, agitation, restlessness, and possible behavioral changes, which could be associated with mood changes.


Q: What is the general expectation for symptom control while using Ventide?

A: Ventide is intended to support the ongoing management of symptoms by maintaining open airways. Official safety documentation emphasizes the need for regular medical review to monitor for any signs of worsening asthma, which would require re-evaluation.


Q: Can Ventide affect bone density over time?

A: Official warnings and precautions note that all inhaled corticosteroids carry a theoretical risk of systemic effects when used long-term, particularly at higher doses. These potential effects include a risk of reducing bone mineral density.


Q: Are there any restrictions on driving or operating machinery while using Ventide?

A: Official labeling generally states that the medicine is unlikely to affect the ability to drive or use machinery. Official guidance suggests that if a user experiences side effects like dizziness or headache, caution may be warranted.


Q: Do the effects of Ventide change after long-term use?

A: Ventide is intended for long-term maintenance use. The need for regular medical review is noted in official documents to monitor for any changes in asthma control or potential side effects that may necessitate treatment adjustment over time.


Q: Why is proper cleaning of the Ventide inhaler important?

A: Official instructions include cleaning guidance to help prevent the build-up of medicine around the mouthpiece, which could otherwise affect accurate dose delivery.

How should Ventide be stored and disposed of?

How to Store and Dispose of Ventide

Official regulatory guidelines for Ventide, a pressurized metered-dose inhaler (pMDI), focus on protecting the stability of the medicine and managing the hazards associated with the pressurized canister.

Storage Requirements

Condition Regulatory Requirement
Temperature Store at room temperature; Do not expose to temperatures higher than 122 F (50 C).
Environmental Protect from frost and direct sunlight; Do not freeze.
Container/Safety Keep in its original container, tightly closed, and out of the sight and reach of children.
Stability Discard when the dose counter displays zero or after the product's expiration date.

Disposal Instructions

Due to the pressurized nature of the canister, Ventide must not be punctured, incinerated, or thrown into a fire, even if empty. The product should not be discarded in household trash or wastewater. Dispose of unused or expired inhalers according to local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ventide found in:

A-Z Index: